REG - Oxford Biomedica PLC - PDMR Dealings

Oxford BioMedicaAnnouncement

12/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221012:nRSL5589Ca&default-theme=true

RNS Number : 5589C  Oxford Biomedica PLC  12 October 2022

 

 

 

PDMR Dealings

 

Oxford, UK - 12 October 2022: Oxford Biomedica plc ("Oxford Biomedica" or "
the Company") (LSE:OXB), a leading gene and cell therapy group, today
announces that Non-Executive Directors Dr. Michael Hayden, Dr Heather
Preston, Dr. Sam Rasty and Catherine Moukheibir have purchased ordinary shares
in the Company pursuant to a trading plan put in place on 7 October 2022.

 

By way of background, and as stated in the Oxford Biomedica 2021 Remuneration
Policy which was approved at the 2021 Annual General Meeting, an additional
fee of up to £50,000 per annum may be paid to any Non-Executive Director
recruited from or based outside of the UK to reflect market levels of
remuneration for Non-Executive Directors not based in the UK, subject to
their agreement that the after tax amount of this additional fee will be used
to acquire Oxford Biomedica shares at market value, which must be retained for
at least 12 months from acquisition. The ordinary shares were all purchased as
317p and the number of ordinary shares purchased along with further
information is set out in the table below:

 

 Name of PDMR         Number of ordinary shares purchased  Number of ordinary shares now held  Total number of ordinary shares held as a percentage of the Company's share
                                                                                               capital
 Dr. Michael Hayden   9,379                                11,289                              0.012%
 Dr. Heather Preston  9,379                                11,614                              0.012%
 Dr. Sam Rasty        9,379                                11,614                              0.012%
 Cathrine Moukheibir  8,910                                11,846                              0.012%

 

The below notification, made in accordance with the requirements of the EU
Market Abuse Regulation, gives further detail of the number of ordinary shares
purchased.

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")
 a)  Name                                     Dr. Michael Hayden
 2.  Reason for the notification
 a)  Position/status                          Non-Executive Director

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code

                                              ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Purchase of shares
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              £3.17     9,379

 e)  Aggregated information

     -    Aggregate volume                    9,379

     -    Aggregated total

                                              £29,999.57
 f)  Date of the transaction                  2022-10-11
 g)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

e)

Aggregated information

-    Aggregate volume

-    Aggregated total

 

 

9,379

 

£29,999.57

f)

Date of the transaction

2022-10-11

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")
 a)  Name                                     Dr. Heather Preston
 2.  Reason for the notification
 a)  Position/status                          Non-Executive Director

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code

                                              ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Purchase of shares
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              £3.17     9,379

 e)  Aggregated information

     -    Aggregate volume                    9,379

     -    Aggregated total

                                              £29,999.57
 f)  Date of the transaction                  2022-10-11
 g)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

e)

Aggregated information

-    Aggregate volume

-    Aggregated total

 

 

9,379

 

£29,999.57

f)

Date of the transaction

2022-10-11

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")
 a)  Name                                     Dr. Sam Rasty
 2.  Reason for the notification
 a)  Position/status                          Non-Executive Director

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code

                                              ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Purchase of shares
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              £3.17     9,379

 e)  Aggregated information

     -    Aggregate volume                    9,379

     -    Aggregated total

                                              £29,999.57
 f)  Date of the transaction                  2022-10-11
 g)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

e)

Aggregated information

-    Aggregate volume

-    Aggregated total

 

 

9,379

 

£29,999.57

f)

Date of the transaction

2022-10-11

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")
 a)  Name                                     Catherine Moukheibir
 2.  Reason for the notification
 a)  Position/status                          Non-Executive Director

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code

                                              ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Purchase of shares
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              £3.17     8,910

 e)  Aggregated information

     -    Aggregate volume                    8,910

     -    Aggregated total

                                              £28,499.59
 f)  Date of the transaction                  2022-10-11
 g)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

e)

Aggregated information

-    Aggregate volume

-    Aggregated total

 

 

8,910

 

£28,499.59

f)

Date of the transaction

2022-10-11

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform, and
is working on programmes from pre-clinical to commercial stage across a range
of therapeutic areas with global partners.

 

Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a
US based subsidiary AAV manufacturing and innovation business, based near
Boston, US.

 

Further information is available at www.oxb.com (http://www.oxb.com) .

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFFFLIITLLLIF